Relating To Harm Reduction.
HB1114 revises Hawaii’s sterile needle and syringe exchange program to move away from a strict one-to-one exchange model and instead allow needs-based distribution of sterile needles and syringes. The bill updates the program’s stated purpose to focus on preventing HIV, hepatitis B, hepatitis C, and other bloodborne infections, while continuing to provide referrals to health and social services, counseling, and substance use disorder treatment referrals. It also broadens the program’s scope by allowing non-injection drug users to receive non-syringe services when resources are available, rather than requiring their exclusion.
The bill adds new statutory definitions for terms such as “needs-based distribution,” “authorized objects” (including items like cookers, cottons, and ties), “program staff,” “residue,” and “syringe exchange participant.” It also expands the program’s reporting requirements to include distribution and collection data, participant demographics, impacts on sharing and high-risk behavior, treatment referrals, HIV transmission effects, and cost-effectiveness. The measure is framed as aligning Hawaii law with CDC guidance and federal model legislation on syringe services programs.
HB1114 would amend Hawaii Revised Statutes chapter 325 governing the sterile needle and syringe exchange program. It repeals the one-to-one syringe limit, authorizes needs-based distribution, permits distribution and possession of specified authorized objects, and creates limited immunity from paraphernalia and drug possession offenses for program staff and participants under defined circumstances. The bill also narrows the program’s exclusion of non-injection drug users and clarifies recordkeeping, reporting, and law enforcement liability provisions, while leaving general controlled-substance laws intact outside the program’s specific protections.
The bill’s stated rationale and structure reflect strong support for harm reduction, public health, and evidence-based syringe services. The findings cite CDC research, cost savings, reduced disease transmission, and improved access to treatment, suggesting a generally favorable policy orientation toward expanding the program. No committee transcripts or votes were provided, so there is no recorded legislative debate or vote history to indicate broader political sentiment beyond the bill’s supportive framing.
The main points of contention are likely to be the shift from one-to-one exchange to needs-based distribution, the expansion of legal protections for participants and staff, and the allowance of non-injection drug users to access some services. Critics could view these changes as too permissive or as potentially complicating enforcement of drug and paraphernalia laws, while supporters would argue they improve disposal practices, reduce infection risk, and better align the program with public health best practices. The bill also specifically addresses law enforcement liability and limits immunity carefully, which suggests an effort to balance harm reduction goals with enforcement concerns.